Business
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) -- DMT310 significantly reduced inflammatory lesions by 45% after only 4 treatments in patients with moderate-to-severe acne -- FDA responses to DMT310 End of Phase 2 meeting package expected by the end this month -SAN DIEGO, CA / ACCESSWIRE / June 8, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) (\"Dermata\" or the \"Company\"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that positive results from its DMT310 Phase 2b study of its once-weekly topical treatment in patients with moderate-to-severe acne vulgaris was published in the prestigious, peer-reviewed Journal of the American Academy of Dermatology (JAAD) and can by found at this link. The study found that once-weekly topical treatment with DMT310 resulted in significant improvements across multiple efficacy endpoints at 12 weeks in patients with moderate-to-severe acne when compared with placebo.\"The publication of our DMT310 Phase 2b results in a journal as prominent as JAAD is a validation of the positive results generated by our lead asset for the potential treatment of acne,\" said Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. \"We continue to be excited by the Phase 2b data that we believe clearly highlights DMT310's ability to address the many challenges with current acne therapies. DMT310's once-weekly application is less burdensome than once or twice a day topical therapies, has a rapid time to treatment effect, and appears to be safe and well tolerated. We believe these attributes, combined with a significant treatment effect, could position DMT310 as a first line treatment for patients with moderate-to-severe acne while also being able to improve patient compliance. We look forward to receiving feedback from FDA on our End of Phase 2 meeting package by the end of June 2023. Assuming positive feedback, we plan to quickly initiate our DMT310 Phase 3 program in moderate-to-severe acne.\"DMT310 Phase 2b Trial DesignThe DMT310 Phase 2b randomized, double-blind, placebo-controlled trial was designed to evaluate the eff...